Oncology

The number of cancers worldwide is steadily increasing. This is due to both population growth and rising life expectancy, as the likelihood of developing cancer increases with age. An unhealthy lifestyle also influences the incidence of cancer.

Among the most common cancers in men is prostate cancer, closely followed by colon– and lung cancer. By contrast, breast cancer is considered the most common cancer and cause of death in women. In second and third place are colorectal cancer and lung cancer. An increase in number of lung cancers is due to increased smoking.

Due to the general increase in cancers, constant intensive research in the field of diagnostics and treatment options is essential.

We offer diagnostic- and parameter-specific panels, as well as large-volume individual donations with extensive clinical documentation of various matrices (e.g. serum, plasma).

Our portfolio includes the following biomarkers

  • Alpha-1-Fetoprotein (AFP)
  • Cancer-Antigen 19-9 (CA 19-9)
  • Cancer-Antigen 125 (CA 125) (PSA)
  • CD25
  • CYFRA 21-1
  • Hodgkin
  • Hepatocellular Carcinoma (HCC)
  • NMP22
  • Prostate Specific Antigen (PSA)
  • PTCL
  • Sarcoidosis
  • Troponin T
Qualification measures:

Growing Organisation; Adaption of Qualification to new market demands, project areas and fields of production

To achieve the goal, that invent persist at the international market, qualification for current and new employees were conducted as follows:

  • training in online-marketing,
  • in contract law and
  • in business basics for executive leadership with scientific background.

New employees acquired competences in the fields of:

  • data protection,
  • medical devices advice,
  • internal auditing,
  • performance assessment of in-vitro diagnostics as well as
  • project management

In the field of production, knowledge of macro programming was gained for digitization.

The measures were funded through the European Social Fund and the state of Brandenburg for the period 2019 – 2021.